<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497612</url>
  </required_header>
  <id_info>
    <org_study_id>DRI12805</org_study_id>
    <secondary_id>U1111-1155-7960</secondary_id>
    <nct_id>NCT02497612</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</brief_title>
  <acronym>FALCI</acronym>
  <official_title>A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To determine whether a single dose combination of OZ439 (Artefenomel)/FQ (Ferroquine) is an
      efficacious treatment for uncomplicated Plasmodium falciparum malaria in adults and children.

      Secondary Objectives:

      - To evaluate the efficacy of OZ439 (Artefenomel)/FQ (Ferroquine): .To determine the
      incidence of recrudescence and re-infection. .To determine the time to relief of fever and
      parasite clearance.

        -  To evaluate the safety and tolerability of OZ439 (Artefenomel)/FQ (Ferroquine).

        -  To evaluate the pharmacokinetics of OZ439 (Artefenomel)/FQ (Ferroquine).

        -  To explore in vitro drug resistance of P. falciparum infecting patients &gt;14 years old in
           Vietnamese sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration will be up to 67 days for each patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 25, 2015</start_date>
  <completion_date type="Anticipated">July 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Polymerase Reaction Chain (PCR)-adjusted Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with PCR - adjusted ACPR</measure>
    <time_frame>Day 42 and Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with PCR - crude ACPR</measure>
    <time_frame>Day 28, Day 42, and Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-emergence</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recrudescence</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, including Serious Adverse Events (SAE), Adverse Event of Special Interest (AESI) and Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to Day 63 or event resolution</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reinfection</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Reduction Rate</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">662</enrollment>
  <condition>Plasmodium Falciparum Infection</condition>
  <arm_group>
    <arm_group_label>Ferroquine Dose 1 + Artefenomel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine Dose 1 single dose + artefenomel fixed single dose, oral take, for patients &gt;14 years old &amp; body weight ≥35 kg.
Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients &lt;35 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine Dose 2 + Artefenomel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine Dose 2 single dose + artefenomel fixed single dose, oral take, for patients &gt;14 years old &amp; body weight ≥35 kg.
Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients &lt;35 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine Dose 3 + Artefenomel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine Dose 3 single dose + artefenomel fixed single dose, oral take, for patients &gt;14 years old &amp; body weight ≥35 kg.
Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients &lt;35 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferroquine Dose 4 + Artefenomel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferroquine Dose 4 single dose + artefenomel fixed single dose, oral take, for patients &gt;14 years old &amp; body weight ≥35 kg.
Ferroquine weight-adjusted single dose + artefenomel weight adjusted dose, oral take, for patients &lt;35 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferroquine SSR97193</intervention_name>
    <description>Pharmaceutical form:Capsules Route of administration: oral</description>
    <arm_group_label>Ferroquine Dose 1 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 2 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 3 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 4 + Artefenomel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artefenomel</intervention_name>
    <description>Pharmaceutical form:Granules for suspension Route of administration: oral</description>
    <arm_group_label>Ferroquine Dose 1 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 2 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 3 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 4 + Artefenomel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules Placebo capsules are used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No patient will receive placebo only.</description>
    <arm_group_label>Ferroquine Dose 1 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 2 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 3 + Artefenomel</arm_group_label>
    <arm_group_label>Ferroquine Dose 4 + Artefenomel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Male or female patient aged &gt;6 months old and &lt;70 years old:

          -  Cohort 1 = 14 years &lt; age &lt;70 years and body weight ≥35 kg.

          -  Cohort 2 = 5 years &lt; age ≤14 years.

          -  Cohort 3 = 2 years &lt; age ≤5 years.

          -  Cohort 4 = 6 months &lt; age ≤2 years. Body weight ≥5 kg and ≤90 kg.

        Presence of mono-infection by P. falciparum with:

          -  Fever, as defined by axillary temperature ≥37.5 C or oral/rectal/tympanic temperature
             ≥38 C, or history of fever in the previous 24 hours (history of fever must be
             documented) and,

          -  Microscopically (blood smear) confirmed parasite infection, ranging from 1000 to 100
             000 asexual parasites/µL of blood.

        Informed Consent Form signed by the patient or by the legally acceptable representative of
        the minor patient.

        Exclusion criteria:

        Presence of severe malaria.

        Anti-malarial treatment:

          -  With piperaquine -based compound, mefloquine, naphthoquine or
             sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their inhibition of
             new infections has fallen below 50%).

          -  With amodiaquine or chloroquine within the previous 4 weeks.

          -  With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial
             treatment or antibiotics with antimalarial activity (including cotrimoxazole,
             tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14
             days.

          -  With any herbal products or traditional medicines, within the past 7 days. Known
             history or evidence of clinically significant disorders. Previous treatment within 5
             times the half-life or within the last 14 days, whichever the longest which are: P-gp
             substrates, CYP2D6 main substrates and/or strong CYP2C or CYP3A inhibitors and/or
             moderate inhibitors but inhibiting both CYP2C and CYP3A and/or CYP inducers.

        Mixed plasmodium infection. Severe vomiting. Severe malnutrition. Laboratory parameters
        with clinical significant abnormalities and/or reaching critical values. For Liver Function
        Test. Aspartate transferase [AST &gt;2 ULN], or alanine transferase [ALT &gt;2 ULN] or total
        bilirubin &gt;1.5 ULN.

        Presence of Hepatitis A Immunoglobulin M (HAV-IgM), Hepatitis B surface antigen (HBsAg) or
        Hepatitis C antibody (HCV Ab).

        Have received an investigational drug within the past 4 weeks. Previous participation in
        any malaria vaccine study or received malaria vaccine in any other circumstance.

        Measles and yellow fever vaccine injection within the last 15 days and or planned for the
        28 days after randomization.

        Female patient of child bearing potential not willing to use an effective contraceptive(s)
        method(s) for the duration of the study.

        Positive serum or urine beta-human chorionic gonadotropin (ß-HCG) pregnancy at study
        screening for female participants of childbearing potential.

        Breastfeeding women. Male patient having a partner of child bearing potential not willing
        to use an effective method of birth control during the study treatment period.

        Splenectomized patients or presence of surgical scar on left hypochondrium. Patient unable
        to drink. Known history of hypersensitivity, allergic or anaphylactoid reactions to
        ferroquine or other amino-quinolines or to OZ439 or OZ277 or to any of the excipients.

        Family history of sudden death or of congenital prolongation of the QTc interval or known
        congenital prolongation of the QTc-interval or any clinical condition known to prolong the
        QTc interval e.g., patients with a history of symptomatic cardiac arrhythmias or with
        clinically relevant bradycardia.

        QTcF &gt;450 ms at screening. Hypokalemia (&lt;3.5 mmol/L), hypocalcemia (&lt;2.0 mmol/L) or
        hypomagnesemia (&lt;0.5 mmol/L) at screening Any treatment known to induce a lengthening of QT
        interval.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 204001</name>
      <address>
        <city>Cotonou</city>
        <country>Benin</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 854001</name>
      <address>
        <city>Nanoro</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 854003</name>
      <address>
        <city>Niangoloko</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 854002</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 266002</name>
      <address>
        <city>Lambaréné</city>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 266001</name>
      <address>
        <city>Libreville</city>
        <zip>B.P. 4009</zip>
        <country>Gabon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 404002</name>
      <address>
        <city>Kisian</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 404003</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 508001</name>
      <address>
        <city>Chokwe</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 800002</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 704003</name>
      <address>
        <city>Binh Phuoc</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 704004</name>
      <address>
        <city>Gia Lai</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 704001</name>
      <address>
        <city>Khanh Hoa</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 704002</name>
      <address>
        <city>Quang Tri</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Kenya</country>
    <country>Mozambique</country>
    <country>Uganda</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

